Charles River Laboratories International (NYSE:CRL) Price Target Raised to $155.00

Charles River Laboratories International (NYSE:CRL) had its price target increased by Barclays from $145.00 to $155.00 in a research report released on Thursday morning,Benzinga reports. They currently have an equal weight rating on the medical research company’s stock.

Several other research firms have also commented on CRL. Mizuho lowered their target price on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a report on Wednesday, April 9th. The Goldman Sachs Group lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Finally, Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their price target for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $176.00.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $138.84 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International has a 12 month low of $91.86 and a 12 month high of $254.15. The firm has a market capitalization of $6.82 billion, a PE ratio of 925.60, a P/E/G ratio of 4.54 and a beta of 1.50. The business has a 50-day moving average of $138.40 and a two-hundred day moving average of $166.32.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.27 earnings per share. As a group, research analysts forecast that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Insider Transactions at Charles River Laboratories International

In related news, COO Birgit Girshick bought 1,514 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO James C. Foster bought 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently bought and sold shares of CRL. Deutsche Bank AG increased its position in shares of Charles River Laboratories International by 77.0% in the first quarter. Deutsche Bank AG now owns 411,419 shares of the medical research company’s stock worth $61,927,000 after acquiring an additional 178,927 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Charles River Laboratories International by 4.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 577,322 shares of the medical research company’s stock worth $86,899,000 after purchasing an additional 24,347 shares in the last quarter. ASR Vermogensbeheer N.V. acquired a new stake in Charles River Laboratories International during the 1st quarter valued at $232,000. Exencial Wealth Advisors LLC purchased a new stake in shares of Charles River Laboratories International in the first quarter valued at $393,000. Finally, J. Safra Sarasin Holding AG boosted its position in shares of Charles River Laboratories International by 6.6% in the first quarter. J. Safra Sarasin Holding AG now owns 8,783 shares of the medical research company’s stock worth $1,322,000 after buying an additional 540 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).